Children 12-18 months old were randomized to receive one dose of a conjugate heptavalent pneumococcal vaccine, two doses of the same vaccine, or one dose of a 23-valent native polysaccharide vaccine. Before immunization, pneumococci included in the conjugate vaccine were isolated from 24% of the children, and an antibiotic-resistant pneumococcus was isolated from 22% of the children. The vaccines had no effect on carriage of non -vaccine-type pneumococci. In contrast, there was a significant reduction in carriage of vaccine-type pneumococci 3 months after one dose and 1 month after a second dose of conjugate vaccine (from 25% to 9% and 7%, respectively; P < .001). No effect was seen after vaccination with the nonconjugate vaccine. One year after immunization, carriage of antibiotic-resistant vaccine-type pneumococci in children receiving conjugate vaccine was lower than that in children receiving the nonconjugate vaccine (4% vs. 14%, P = .042). Conjugate pneumococcal vaccines may reduce spread of pneumococci in the community.
Streptococcus pneumoniae is an important cause of morbidity and mortality in all societies [1] . The main reservoir of pneumococci is the nasopharynx. Many individuals in a population are colonized with S. pneumoniae at any given time, and most children are colonized at some point during the first 2 years of life [2] [3] [4] . Since conjugate Haemophilus influenzae type b vaccines were successful in reducing nasopharyngeal carriage of H. influenzae in children [5] [6] [7] [8] [9] , it is logical to examine if a similar phenomenon occurs after immunization with conjugate pneumococcal vaccines [10, 11] . One study indicated that the likelihood of adults becoming nasopharyngeal carriers of a given pneumococcal type may be reduced by immunization with specific polysaccharides [12] ; however, another study could not duplicate this finding [13] .
Resistance of pneumococci to antimicrobial agents, which was first reported in the mid-1960s [14, 15] , is increasing worldwide and has an enormous impact on clinicians, microbiologists, drug manufacturers, and public health authorities [10, [16] [17] [18] . Antibiotic-resistant pneumococci are more often carried by infants and young children than by adults [19 -21] . Furthermore, since most of the resistant strains belong to only a limited number of serotypes, which are also among the most common causes of pediatric infections [10, 22 -25] , conjugate vaccines aimed at these antigens may provide a useful tool to reduce nasopharyngeal carriage and limit the spread of resistant pneumococci.
A high prevalence of nasopharyngeal colonization with S. pneumoniae in general and with antibiotic-resistant strains in particular was found in southern Israel, with the resistant strains appearing in early infancy and increasing sharply toward the end of the second year of life [26] . In Israel, resistant pneumococci are a prevalent cause of both otitis media and invasive infections [21] .
Great efforts are being made to develop efficacious antimicrobial agents capable of overcoming resistance; however, the simplest and potentially most effective means of dealing with this rising problem may be to prevent its occurrence by immunization [10, 11, 27] .
This open-label, comparative, randomized study was conducted to determine if administration of a heptavalent pneumococcal conjugate vaccine (containing capsular polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated individually to the outer membrane protein complex of Neisseria meningitidis serogroup B) to children 12-18 months old would result in reduction of nasopharyngeal carriage of vaccine-type pneumococci that are susceptible or resistant to antimicrobial agents. This age group was chosen because day care attendance increases sharply during the second year of age in Israel, and carriage of resistant strains was previously found to be highly associated with day care attendance [20, 21, 28] . Study design. Children were enrolled at 12, 15, and 18 months of age. In each age group, children were randomized into 3 groups: groups A, B, and C. Group A received one dose of conjugate heptavalent vaccine; B received one dose of PNEUMOVAX 23, and C received two doses of conjugate heptavalent vaccine 3 months apart (at 12 and 15 months, 15 and 18 months, or 18 and 21 months) (figure 1). Randomization was done within each age group to avoid uneven distribution of age groups between the study groups.
Patients and Methods

Patients
Groups A and B were examined before vaccination and 1 and 12 months after vaccination. Group C was examined before vaccination, 3 months after the first dose (before dose two), 4 months after dose one (1 month after dose two), and 15 months after the first dose (12 months after dose two). At each visit and at the last follow-up visit, a blood sample was obtained for serology, and a nasopharyngeal swab sample was obtained for culture. At their last follow-up visit, children in groups A and B were 24, 27, or 30 months old, and those in group C were 27, 30, or 33 months old.
Concurrent vaccines were given so that subjects would be in compliance with the regular immunization program in Israel: At age 12 months, infants received the pneumococcal vaccines, diphtheria-tetanus-whole cell pertussis-inactivated poliovirus vaccine Laboratory measurement. Blood was kept refrigerated until processed in the laboratory (within 16 h). Thereafter, serum was separated and kept frozen (-70°C) until shipped to Merck Research Laboratories, where the antibody assays were done. Pneumococcal IgG antibody levels were measured by ELISA [29] .
Bacteriology. Nasopharyngeal samples were obtained with a swab and placed in MWl73 Amies medium (Transwab; Medical Wire and Equipment, PotIey, UK) for processing (within 4 h) at the Clinical Microbiology Laboratory, Soroka University Medical Center.
Swabs were plated immediately onto trypticase agar medium containing 5% sheep blood and then incubated aerobically at 35°C for 48 h. Presumptive identification of pneumococci was based on presence of a-hemolysis and inhibition by optochin; confirmation was by a positive slide agglutination test (Phadebact; Pharmacia Diagnostics, Uppsala, Sweden). The quellung reaction was used to type recovered pneumococci according to established procedures [30] . Susceptibility to penicillin, trimethoprim-sulfamethoxazole, erythromycin, clindamycin, tetracycline, and chloramphenicol was tested by the disk-diffusion method of Bauer and Kirby (as described in [31D. Isolates exhibiting inhibition zones~19 mm with a I-J1g oxacillin disk were further tested for susceptibility to penicillin by the E-Test (PDM Epsilometer; AB Biodisk, Solna, Sweden) [32] . Isolates with an E-Test MIC of 0.1-1.0 J1g/mL were considered intermediately resistant, and those with MICs > 1.0 J1g/mL were defined as highly resistant [33] .
All laboratory work was conducted in a blinded manner. Susceptibility testing was done by a technician unaware of the serotypes, 
Results
Population. In total, 263 children were enrolled in the study: 92 at age 12 months, 81 at age 15 months, and 90 at age 18 months. Of the children, 97 were randomized to group A, 68 to group B, and 98 to group C. The 3 age groups were equally distributed among groups A, B, and C.
At enrollment, information on day care attendance was available for 257 children: 52 (20%) attended a day care. At the end of follow-up, information was available for 184 children: 85 (46%) attended day care. No difference in attendance was observed between the groups.
Culture. A nasopharyngeal swab sample for culture was obtained from 247 (94%) of the 263 study subjects before the first vaccine dose. One month after the first dose, samples were obtained from 65% (111/165) of groups A and B, and 3 months after the first dose (before dose two), a sample was obtained from 78 (80%) of 98 children in group C. One month after the second dose, a sample was obtained from 64 (65%) of 98 children in group C. One year after the first dose, samples were obtained from 135 (82%) of 165 children in groups A and B, and 1 year after dose two, they were obtained from 57 (58%) of 98 children in group C.
Before immunization, S. pneumoniae was isolated from 109 (44%) of 247 12-to 18-month-old children (table 1) . Seven of the isolates were not retrievable and could not be typed; therefore, the children from whom the isolates were derived were not entered into the analysis. Of the remaining 240 children, 58 (24%) carried types included in the heptavalent pneumococcal conjugate vaccine (vaccine-type pneumococci). Susceptibility testing was not done for 1 isolate, and the child from whom it was isolated was also not entered in the data analysis. Of the remaining 239 children, 52 (22%) carried isolates that were resistant to at least one tested antibiotic, 30 (13%) were resistant to at least 2 antibiotics, and 34 (14%) were resistant to penicillin.
Of the 102 serotyped isolates, 58 (57%) were vaccine-type pneumococci: There were 1 of type 4, 11 of 6B, 7 of 9V, 6 of 14,1 of 18C, 7 of 19F, and 25 of23F. Of the 44 non-vaccinetype isolates, those most commonly isolated were type 6A (20%) and 19A (14%). Resistance was more prevalent among the 58 vaccine-type isolates than the 44 isolates not included in the vaccine (table 2). Resistance to ;::,2 drugs was 25 times more prevalent among the vaccine-type than the non-vaccinetype isolates (P < .01).
Although there was a high prevalence of isolates resistant to penicillin, none had a MIC > 1.0 j.lg/mL. None of the isolates was resistant to clindamycin or chloramphenicol.
Effect ofvaccine on carriage ofpneumococci. Carriage of the non-vaccine-type pneumococci was 15%-22% in the 3 
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groups before immunization and was not affected by vaccine at any point during the I-year follow-up (figure 2). One year after immunization, however, carriage of non-vaccine-type strains had increased to 32%-39% in all 3 groups; no difference was found between groups. One year after immunization, the number of resistant non -vaccine-type pneumococci had not increased from baseline: 12 (27%) of the 44 non -vaccinetype pneumococci isolated before immunization were resistant to at least one antibiotic, versus 15 (23%) of 66 isolates 1 year after immunization. No significant difference between groups was observed; thus, there was no selection by vaccine toward carriage of resistant non -vaccine-type pneumococci.
There was, however, a vaccine effect on carriage of vaccinetype strains (figure 2). Carriage was similar among the 3 groups before vaccination, and 1 month after administration of the first doses of conjugate (group A) and nonconjugate (group B) vaccines, there was no difference in carriage and no difference between the 2 groups. However, in group C 3 months after the first dose of conjugate vaccine, there was a marked and significant reduction of carriage, from 25% (23/91) to 9% (7/78), and 1 month after the second dose, carriage was reduced further to 7% (5/67) (P = .007, prevaccination vs. after dose one or two). One year after immunization, this effect was still apparent in groups A and C, who had 14% (11/78) and 11% (6/57) carriage, respectively, versus 21% (18/84) and 25% (23/91), respectively, 1 year earlier (P < .00 1, groups A and C combined and compared with preimmunization carriage). In contrast, for group B, no difference in carriage of vaccine-type strains was seen at any point during follow-up (25% [14/57] vs. 28% [17/ 59] for the previous year). Thus, 1 year after immunization, the group given nonconjugate vaccine had a higher prevalence of vaccine-type pneumococci (25% [14/57]) than the 2 groups given conjugate vaccine (groups A and C combined , 13% [I 7/ 135]; P = .065).
Antibiotic-resistant vaccine-type pneumococci carriage showed no difference at any point in children who received nonconjugate vaccine (group B) (figure 2). For group C, however, there was a reduction in carriage 3 months after the first dose of conjugate vacc ine and immediately after the second dose (from 18/91 [20%] to 7/78 [9%], P == .06). One year after immunization, carriage of resistant vaccine-type pneumococci remained low for groups A and C (4% [3/78] and 5% [3/57], respectively, vs. 14% [8/57] in group B; P < .01 for groups A and C combined vs. preimmunization levels; P = .042 for groups A and C vs, group B) .
Thus, a significant reduction in both vaccine-type pneumococcal carriage and resistant vaccine-type pneumococcal carriage was observed 3 months after one dose of conjugate vaccine, and the effect was still present after 1 year of follow-up. In contrast, no such effect was observed in the group receiving nonconjugate vaccine. No difference in carriage of vaccinetype pneumococci or antibiotic-resistant vaccine-type pneumococci was found after I year between groups A and C. Table 3 shows the antibody response by the 3 study groups to vaccine. After one dose, all groups showed response, but the response for types 6B and 14 was higher in the 2 groups receiving conjugate vaccine (groups A and C) than in the group receiving nonconjugate vaccine (group B), despite the fact that NOTE. After dose 1, I month after 1st dose for groups A and B; 3 months after 1st dose for group C. After dose 2, 1 month after 2nd dose given at 3 months after l st dose-for group Conly. 12 months after last dose, 12 months after only dose given in groups A and B; 12 months after 2nd dose in group C.
the nonconjugate vaccine had a higher polysaccharide content for each of the components. Group C children were primed by the first dose of conjugate vaccine, as judged by the typical booster response to the second dose, which was administered 3 months later: Compared with the geometric mean levels (GMLs) after the first dose, the GMLs rose by 3.1-, 4.8-, 3.9-, 4.5-, 3.5-, 3.5-, and 1.6-fold after the second dose for types 4, 6B, 9V, 14, 18C, 19F, and 23F, respectively. One year after the last dose, both the GML and the number of children with levels > 1.0 ,ug/mL were higher among subjects receiving either one or two doses of conjugate vaccine compared with those receiving the nonconjugate vaccine for the 2 less immunogenic serotypes (types 6B and 23F).
Since the most commonly carried serotypes were 6B and 23F, we investigated the potential for these organisms to cause spontaneous boosting of antibody levels during the I-year follow-up after one dose of conjugate (group A) or nonconjugate (group B) vaccine. For group A subjects with type 6B, the GML rose from 1.11 ,ug/mL 1 month after immunization to 2.30 ,ug/mL 1 year after immunization, and the percentage of children with levels> 1.0 ,ug/mL rose from 52% to 76%. For group A subjects with type 23F, the GML remained at the same level at the I-year follow-up (1.21 ,ug/mL at 1 month and 1.12 ,ug/mL at 1 year after immunization). In general, 1 year after the last dose, no differences in GML or percentage of children with levels > 1.0 ,ug/mL were observed between those receiving one or two doses of conjugate vaccine. In contrast, children with serotype 23F who received nonconjugate vaccine (group B) had a decrease in GML from 1.18 to 0.44 p,g/mL and a respective decrease in the percentage of children with antibody levels> 1.0 p,g/mL. To see if there was a correlation between antibody levels and pneumococcal carriage, we compared antibody levels for children colonized with vaccine-type pneumococci at the end of the I-year follow-up with antibody levels for children not colonized with the same serotype. There were 24 children who were colonized with vaccine-type pneumococci and who had blood samples available for antibody determination. We compared these children with those without colonization of the respective serotype by dividing the individual patient's antibody level by the GML of the group to which the vaccinee belonged (table 4) . No correlation between serum antibody levels and colonization was found, since in all 3 groups, > 50% ofthe colonized vaccinees had antibody levels to the colonizing serotype that were higher than the GML ofthe respective group. Furthermore, in 17 (71%) of the 24 colonized patients, serum antibody levels were> 1.0 p,g/mL, and in 12 they were >3.0 p,g/mL.
Discussion
To our knowledge, this is the first report showing that carriage of vaccine-type pneumococci was reduced following administration of a conjugate pneumococcal vaccine. Various conjugate vaccines against invasive infections caused by H. infiuenzae type b have nearly eliminated the disease when incorporated into mass immunization programs [34] . It is believed that an important component of that success was the ability of the H infiuenzae type b conjugate vaccines to reduce respiratory carriage of H. inftuenzae type b [5] [6] [7] [8] [9] , similar to our findings with the conjugate vaccine and pneumococci. In one study, H. influenzae carriage was examined 1 year after immunization and was still reduced [9] . It remains to be determined if reduction of pneumococcal carriage will occur with other conjugate pneumococcal vaccines and if acquisition can be prevented in the first year of life, when vaccine is administered starting at 2 months of age.
The high prevalence of pneumococcal carriage associated with day care attendance reported among infants and young children [26, 28, 35, 36] facilitates spread of resistant pneumococci to the carriers' family [21, 26] . We hope that reduction of spread of the organism through immunization can be achieved. This concept is further supported by a previous experience with H. infiuenzae type b: A reduction in carriage by immunized children was associated with a decreased rate of H. infiuenzae type b morbidity in adults and invasive disease in their younger siblings [6] .
We observed a significant reduction of pneumococcal nasopharyngeal carriage 3 months after the first dose of conjugate vaccine but not after 1 month. This finding is consistent with previous data on the use of pneumococcal [12] and meningococcal [37] nonconjugate vaccines in adults and H influenzae type b conjugate vaccine [38] in infants. Those studies showed that vaccines against encapsulated organisms could prevent acquisition of the organisms but not terminate carriage of them if present at the time of vaccination. Thus, we speculate that the antibody levels achieved 3 months after immunization are sufficient to prevent acquisition of vaccine-type pneumococci in many children.
In the present study, the effect of the heptavalent conjugate vaccine was compared with the effect of a nonconjugate 23-valent polysaccharide vaccine but not with that of a placebo. We cannot rule out a certain effect of the 23-valent polysaccharide on pneumococcal carriage, as has been described previously in adults vaccinated with nonconjugate pneumococcal [12] and meningococcal [37] vaccines; however, others could not duplicate the reduction in carriage after nonconjugate pneumococcal vaccination of adults [13] or nonconjugate H. influenzae polysaccharide vaccination of children [39] . Furthermore, 1 year after immunization in our study, the carriage rate of pneumococci not included in the heptavalent conjugate vaccine but included in the 23-valent nonconjugate vaccine was similar in recipients of the two vaccines. This suggests no effect of the nonconjugate vaccine on carriage.
One year after immunization, nasopharyngeal pneumococcal carriage was reduced among those who received the conjugate vaccine compared with those who received the nonconjugate vaccine, but no difference in carriage was observed between those who received one compared with two doses of conjugate vaccines. This observation suggests that either the immunity provided by one dose of the conjugate vaccine was sufficient to produce the observed prolonged effect or that natural boosting of immunity occurred in those who received one dose of conjugate vaccine after exposure to vaccine-type strains. The fact that natural boosting was observed in our study for the 2 most commonly carried serotypes, namely 6B and 23F, suggests a role of the latter mechanism in prevention of colonization. This effect of natural boosting is not surprising since it has been shown for H. influenzae type b [40] and pneumococci [41] [42] [43] that boosting with native polysaccharide after priming with conjugate vaccine is feasible. Of note, immunologic memory in young infants primed with three doses of heptavalent conjugate pneumococcal vaccine was observed after they were immunized with the 23-valent native polysaccharide vaccine [29] .
Although a correlation between humoral immunity to H. influenzae type b and mucosal anti -H. influenzae type b immunity has been shown [44] , our limited results do not support such a direct correlation, since antibody levels as high as >3.0 f.Lg/mL to the colonizing serotype were found in 50% of the colonized vaccinees. Studies looking more specifically at the response of mucosal immunity and its correlation to humoral immunity after immunization with conjugate pneumococcal vaccine must be considered before a firm conclusion can be drawn.
Certain limitations of our methodology could influence the interpretation of our results. First, it is important to understand that when no pneumococci are isolated from a nasopharyngeal swab, it may reflect continuing colonization levels below the sensitivity threshold of the culture. If this occurs, it needs to be established whether the presence of such low-grade colonization is still associated with transmission. Second, when a pneumococcus was cultured from the nasopharyngeal specimen, only 1 colony was obtained for typing. While there is no doubt that such a technique will predict the dominant population of colonizing serotypes, it may miss in some cases a simultaneous carriage with other serotypes. Despite these limitations, we believe that the impressive reduction in carriage of resistant vaccine-type strains by administration of a conjugate vaccine observed in our study may reduce transmission of these strains, but this still needs to be demonstrated in large-scale studies.
